Valeritas Holdings, Inc.

Equities

VLRXQ

US91914N3017

Medical Equipment, Supplies & Distribution

Delayed OTC Markets Other stock markets			5-day change	1st Jan Change
- ^USD	-.--%		-4.76%	-96.52%

2020	Valeritas Holdings, Inc. Went Out of Business	CI
2020	First Amended Combined Joint Liquidation Plan & Disclosure Statement Approved for Valeritas Holdings, Inc.	CI

VALERITAS HOLDINGS INC. : Other Events, Financial Statements and Exhibits (form 8-K)

December 09, 2019 at 05:19 pm EST

Item 8.01. Other Events.

On December 9, 2019, Valeritas Holdings, Inc. announced positive data from a preclinical pharmacokinetic (PK) study of cannabidiol (CBD) subcutaneous infusion was presented as a late-breaking poster presentation at the American Epilepsy Society 2019 Annual Meeting in Baltimore, Maryland.

The full text of the press release is filed as Exhibit 99.1 hereto and incorporated herein by reference.

Item 9.01. Financial Statements and Exhibits.



(d)  Exhibits.
Exhibit No.   Description
99.1            Press release dated December 9, 2019.

--------------------------------------------------------------------------------

Latest news about Valeritas Holdings, Inc.

Valeritas Holdings, Inc. Went Out of Business	20-06-30	CI
First Amended Combined Joint Liquidation Plan & Disclosure Statement Approved for Valeritas Holdings, Inc.	20-06-08	CI
First Motion for Exclusivity Period Extension Approved For Valeritas Holdings, Inc.	20-06-03	CI
First Motion for Exclusivity Period Extension Filed by Valeritas Holdings, Inc.	20-05-21	CI
Combined Disclosure Statement and Liquidation Plan Approved for Solicitation Purpose on Interim Basis for Valeritas Holdings, Inc.	20-04-21	CI
First Amended Combined Joint Liquidation Plan & Disclosure Statement Filed by Valeritas Holdings, Inc.	20-04-15	CI
Combined Joint Liquidation Plan & Disclosure Statement Filed by Valeritas Holdings, Inc.	20-04-06	CI
Valeritas Holdings, Inc. Announces Management Changes	20-04-02	CI
Zealand Pharma A/S completed the acquisition of substantially all assets of Valeritas Holdings, Inc.	20-04-01	CI
Motion for Asset Sale Approved for Valeritas Holdings, Inc.	20-03-20	CI
Final DIP Financing Approved for Valeritas Holdings, Inc.	20-03-13	CI
Notice for Auction Cancellation Filed by Valeritas Holdings, Inc.	20-03-13	CI
Bidding Procedure Approved for Valeritas Holdings, Inc.	20-03-06	CI
Valeritas Holdings, Inc. Terminates Joseph Saldanha as Chief Business Officer, Effective from March 6, 2020	20-02-28	CI
Valeritas Holdings, Inc.(OTCPK:VLRX.Q) dropped from NASDAQ Composite Index	20-02-19	CI
The United States Bankruptcy Court for the District of Delaware Enters an Order Granting an Interim Approval to Valeritas Holdings, Inc.'s Proposed Senior Secured Priming Debtor-In-Possession Financing Facility	20-02-14	CI
Interim DIP Financing Approved for Valeritas Holdings, Inc.	20-02-14	CI
Asset Purchase Agreement Filed by Valeritas Holdings, Inc.	20-02-14	CI
Valeritas Holdings, Inc.(NasdaqCM:VLRX) dropped from S&P TMI Index	20-02-12	CI
Motion for Joint Administration Approved for Valeritas Holdings, Inc.	20-02-11	CI
Motion for Asset Sale Filed by Valeritas Holdings, Inc.	20-02-10	CI
Valeritas Holdings, Inc. Filed for Bankruptcy	20-02-09	CI
Motion for Joint Administration Filed by Valeritas Holdings, Inc.	20-02-08	CI
Zealand Pharma A/S entered into a stalking horse agreement to acquire substantially all assets of Valeritas Holdings, Inc.	20-02-08	CI
Valeritas Holdings, Inc. Announces Appointment of Melanie Hansen as Treasurer and Principal Accounting Officer, Effective January 13, 2020	20-01-10	CI

Chart Valeritas Holdings, Inc.

Duration

Period

More charts

Company Profile

Valeritas Holdings, Inc. is a United States-based medical technology company. The Company's product, V-Go Wearable Insulin Delivery device (V-Go), is a wearable, basal-bolus insulin delivery device for adult patients requiring insulin that enables patients to administer a continuous preset basal rate of insulin over 24 hours. V-Go is a small wearable and completely disposable insulin delivery device that a patient adheres to his or her skin every 24 hours. V-Go enables patients to closely mimic the body's normal physiologic pattern of insulin delivery throughout the day and to manage their diabetes with insulin without the need to plan a daily routine around multiple daily injections. It has developed V-Go utilizing its h-Patch platform as a patient-focused solution to address insulin therapies. Its h-Patch platform facilitates the subcutaneous delivery of injectable medicines to patients across a range of therapeutic areas.

Sector

Medical Equipment, Supplies & Distribution

More about the company

Sector Other Medical Equipment, Supplies & Distribution

	1st Jan change	Capi.
VALERITAS HOLDINGS, INC.	-96.52%	167K
ABBOTT LABORATORIES	-4.82%	182B
MEDTRONIC PLC	+1.38%	110B
BECTON, DICKINSON AND COMPANY	-2.82%	68.11B
DEXCOM, INC.	+0.69%	50.53B
CENCORA, INC.	+8.54%	44.8B
HOYA CORPORATION	+2.84%	40.7B
METTLER-TOLEDO INTERNATIONAL, INC.	+20.50%	32.25B
WEST PHARMACEUTICAL SERVICES, INC.	+1.72%	26.53B
TERUMO CORPORATION	+15.25%	25.02B

Other Medical Equipment, Supplies & Distribution